Targeted therapy for thyroid cancer: An updated review of investigational agents.

摘要: The treatment of thyroid cancer is evolving. molecular mechanisms carcinogenesis for many cancers have been investigated, and yielded targets potential therapies. These include VEGFR in the all cancers, BRAF papillary cancer, RET medullary (MTC). Many promising drugs that target one or more these proteins are currently being evaluated, including sorafenib sunitinib, both which still under development but approved use other malignancies. In addition, compounds such as vandetanib (AstraZeneca plc) XL-184 (Bristol-Myers Squibb Co/Exelixis Inc) demonstrated activity early-phase clinical trials MTC tested further randomized trials.